WhatsApp
backNews Article

Neuland Laboratories Reports Rs.1107.2 Crores Revenue for H1 FY27 and Invests in Kakinada Expansion

Q2 FY27 revenue at Rs.457.2 Crores amid market fluctuations; new peptide facility commissioned and R&D center planned for early next year

Neuland Laboratories Limited announced Rs.457.2 Crores revenue for Q2 FY27 and Rs.1107.2 Crores for H1 FY27, driven by commercial CMS molecules and GDS specialty portfolio. The company reported EBITDA of Rs.104.6 Crores with a 22.9% margin in Q2, while profit after tax was Rs.51.1 Crores. Neuland undertook capital investments totaling Rs.261 Crores and acquired 134 acres in Kakinada for future expansion, with plans to inaugurate a new R&D center early next year.

06 Nov 2026|NEULANDLAB-0.44%
Neuland Laboratories LimitedNEULANDLABEarnings Call Transcript

Neuland Laboratories Limited

Earnings Call Transcript

Neuland Laboratories Limited reported total income of Rs.457.2 Crores for Q2 FY27 and Rs.1107.2 Crores for the first half of FY27, supported by commercial CMS molecules and contributions from its GDS business. The company reported an EBITDA margin of 22.9% and a net profit of Rs.51.1 Crores in Q2.

The quarter witnessed a decline in total income compared to Rs.516.1 Crores in Q2 FY26, with gross margin slightly decreasing to 59.4%. EBITDA stood at Rs.104.6 Crores (22.9% margin), while profit after tax was Rs.51.1 Crores. Earnings per share were Rs.39.85.

Input cost pressures rose due to geopolitical tensions affecting raw materials and logistics. Working capital days increased to 104 compared to 84 in the previous quarter. Capital expenditure for H1 FY27 was Rs.261 Crores, with free cash flow of Rs.99 Crores and a net negative debt position of Rs.208 Crores.

Neuland's CEO explained the inherent lumpiness in CDMO revenue reflecting customer molecule development timelines. CMS commercial molecules remain a key revenue driver, supplemented by the Prime portfolio in GDS. The company witnessed strong proposal activity, signaling potential future growth.

The GDS segment filed two DMFs for Fezolinetant and Ivacaftor, strengthening its portfolio. Neuland commissioned a new peptide block at Unit One and plans to inaugurate a process R&D center in Genome Valley by early next year.

The company acquired 134 acres of land at Kakinada, Andhra Pradesh, providing scope for long-term capacity expansion and strategic flexibility in response to customer demand.

Highlights

  • Q2 FY27 total income: Rs.457.2 Crores vs Rs.516.1 Crores in Q2 FY26.
  • H1 FY27 total income: Rs.1107.2 Crores vs Rs.816.7 Crores in H1 FY26.
  • Q2 FY27 gross margin: 59.4%; EBITDA: Rs.104.6 Crores with 22.9% margin.
  • Q2 FY27 profit after tax: Rs.51.1 Crores; EPS: Rs.39.85 per share.
  • Input cost pressures from geopolitical conflicts impacted raw materials and logistics costs.
  • Working capital increased to 104 days; capital expenditure at Rs.261 Crores in H1 FY27 with free cash flow of Rs.99 Crores and net debt negative Rs.208 Crores (cash surplus).  |Acquired 134 acres land in Kakinada for future expansion plans.

Key Data Snapshot

Q2 FY27 Total IncomeRs.457.2 Crores
Q2 FY26 Total IncomeRs.516.1 Crores
H1 FY27 Total IncomeRs.1107.2 Crores
H1 FY26 Total IncomeRs.816.7 Crores
Q2 FY27 Gross Margin59.4%
Q2 FY27 EBITDARs.104.6 Crores
Q2 FY27 EBITDA Margin22.9%
Q2 FY27 Profit After TaxRs.51.1 Crores
Q2 FY27 EPSRs.39.85 per share
H1 FY27 Capital ExpenditureRs.261 Crores
H1 FY27 Free Cash FlowRs.99 Crores
Net Debt PositionNegative Rs.208 Crores
Working Capital Days104 days

What happened

  • Neuland Laboratories reported Rs.457.2 Crores revenue in Q2 FY27 and Rs.1107.2 Crores in H1 FY27.
  • The revenues were primarily driven by commercial CMS molecules and the Prime portfolio within GDS.
  • The company reported EBITDA of Rs.104.6 Crores with a margin of 22.9% and net profit of Rs.51.1 Crores in Q2 FY27.
  • Capital expenditure for the first half of FY27 was Rs.261 Crores, reflecting ongoing investment.
  • Neuland acquired approximately 134 acres of land in Kakinada, Andhra Pradesh, to support future expansion plans.

Key details

  • Gross margin for Q2 FY27 stood at 59.4%, slightly below the 60.1% in Q2 FY26.
  • Earnings per share for Q2 FY27 were Rs.39.85.
  • Working capital days increased to 104 compared to 84 days in the previous quarter.
  • Free cash flow for H1 FY27 was Rs.99 Crores, while net debt was negative Rs.208 Crores indicating net cash position.
  • Input costs increased due to geopolitical tensions impacting raw material prices and logistics costs.

Operational performance

  • Commercial molecules in CMS and specialty portfolio products in GDS contributed materially to revenues.
  • Two DMFs were filed during the period for Fezolinetant and Ivacaftor, strengthening the GDS portfolio.
  • New peptide block commissioned at Unit One with encouraging traction.
  • Process R&D center at Genome Valley, Hyderabad, expected to be operational by early next year.

Strategic context

  • Neuland highlighted the typical lumpiness in CDMO business driven by client molecule development and shipment schedules.
  • The company is focused on growing CMS contributions alongside GDS and expanding its customer base, including relationships with big pharma.
  • The acquisition of land at Kakinada aims to ensure capacity growth does not constrain future customer opportunities.

More News on Earnings Call Transcript

View all

Latest corporate announcements and market updates in Earnings Call Transcript.

View all news
Neuland Laboratories Reports Rs.1107.2 Crores Revenue | Stockk News